During the past decade, Fundación Arturo López Perez conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 13 clinical trials were completed, i.e. on average, 56.5% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 6 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fundación Arturo López Perez" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Merck Sharp & Dohme LLC" with 5 trials sponsored, "Bristol-Myers Squibb" with 4 trials sponsored, "Daiichi Sankyo, Inc." with 3 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 3 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fundación Arturo López Perez" #1 collaborator was "Breast International Group" with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Eisai Inc." with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "Astellas Pharma Inc" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Fundación Arturo López Perez" are "Breast Cancer" (4 trials), "Prostatic Neoplasms" (4 trials), "Colorectal Cancer" (2 trials), "Pancreatic Cancer" (2 trials) and "Renal Cell Carcinoma" (2 trials). Many other conditions were trialed in "Fundación Arturo López Perez" in a lesser frequency.

Most popular intervention types in "Fundación Arturo López Perez" are "Drug" (29 trials), "Biological" (8 trials), "Other" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Paclitaxel" (6 trials), "Pembrolizumab" (5 trials), "Atezolizumab" (4 trials) and "Carboplatin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Fundación Arturo López Perez" are 28 trials for "All" genders, 5 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Fundación Arturo López Perez". undefined are not yet recruiting, 9 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Fundación Arturo López Perez, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Fundación Arturo López Perez, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".